WuXi, a Chinese pharmaceutical company, is under scrutiny by U.S. Congress for its significant role in the American pharmaceutical industry and allegations of stealing genetic information. The company is reported to produce a quarter of the U.S.'s critical drugs and is involved in making key ingredients for multibillion-dollar therapies for diseases such as cancer, obesity, and HIV. This has raised national security concerns among lawmakers, who are seeking to limit the firm's involvement in U.S. pharmaceutical interests. The situation has caused unease within the biotech sector, with fears that legislative actions could impact both the company and U.S. drugmakers.